Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Originally the biggest X-Men rival, Magneto has gone through a lot in the Marvel universe. This is his story. Script by Arantxa Pellme, video edited by Federico Rossi. Getting Worse: China and EU ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along with other updates to help deploy and maintain these agents. It unveiled ...

Zydus Lifesciences Limited announced on March 11, 2025, that it entered into an agreement to acquire a majority stake in Amplitude Surgical. Reports state that Zydus Lifesciences has a tender ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a combination regimen with ivacaftor for the treatment of ...

Abstract: It operates in a Magneto-Thermo-Force coupling environment, when the electromagnetic brake is applied to artillery. The intensive impact force and the temperature rise will both affect the ...

Ver­tex Phar­ma­ceu­ti­cals an­nounced Fri­day af­ter­noon that it won’t move for­ward with its type 1 di­a­betes cell ther­a­py that’s de­liv­ered in a … ...